Print
Email
Print Edition StoriesWednesday, November 18, 2009
Clinical Data’s cardiac stress test hits Phase 3 trials
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Technology to keep seniors healthy
Clinical Data Inc. has begun a Phase 3 trial of its cardiac stress testing agent, Stedivaze, in detecting defects to supplying blood to the heart. The trial is intended to compare the agent to adenosine in myocardial perfusion imaging.
The randomized trial is being conducted with about 750 patients in a time period of up to two years. In addition to running a comparison between Stedivaze and adenosine, it will also analyze cases of side effects such as cheest pain, dizziness, shortness of breath and headache.
Newton-based Clinical Data (Nasdaq: CLDA) announced on Tuesday that it has formed a scientific advisory board for its PGxHealth division, which develops the Familion line of genetic tests.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
